The quantity and quality of worldwide new drug introductions, 1982-2003.
Repository Usage Stats
We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over time, introductions of high-quality NCEs (that is, global and first-in-class NCEs) increased moderately. Both biotech and orphan products enjoyed tremendous growth, especially for cancer treatment. Country-level analyses for 1993-2003 indicate that U.S. firms overtook their European counterparts in innovative performance or the introduction of first-in-class, biotech, and orphan products. The United States also became the leading market for first launch.
Investigational New Drug Application
Orphan Drug Production
Published Version (Please cite this version)10.1377/hlthaff.25.2.452
Publication InfoGrabowski, Henry G; & Wang, YR (2006). The quantity and quality of worldwide new drug introductions, 1982-2003. Health Aff (Millwood), 25(2). pp. 452-460. 10.1377/hlthaff.25.2.452. Retrieved from http://hdl.handle.net/10161/6725.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Professor Emeritus of Economics
Professor Grabowski specializes in the investigation of economics in the pharmaceutical industry, government regulation of business, and the economics of innovation. His specific interests within these fields include intellectual property and generic competition issues, the effects of government policy actions, and the costs and returns to pharmaceutical R&D. He has been publishing research papers for over four decades, from his earlier work, “The Effects of Regulatory Policy on the Incentives